List of Excipients in Branded Drug TRIHEXYPHENIDYL HYDROCHLORIDE

Generic Drugs Containing TRIHEXYPHENIDYL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
PAI Holdings, LLC dba PAI Pharma	trihexyphenidyl hydrochloride	0121-0658	ALCOHOL
PAI Holdings, LLC dba PAI Pharma	trihexyphenidyl hydrochloride	0121-0658	ANHYDROUS CITRIC ACID
PAI Holdings, LLC dba PAI Pharma	trihexyphenidyl hydrochloride	0121-0658	METHYLPARABEN

What are the Most Frequently-Used Excipients in TRIHEXYPHENIDYL HYDROCHLORIDE?

# Of NDCs	Excipient
4	ALCOHOL
4	ANHYDROUS CITRIC ACID
7	ANHYDROUS DIBASIC CALCIUM PHOSPHATE

Excipient Strategy and Commercial Opportunities for Trihexylphenidyl Hydrochloride

Last updated: February 27, 2026

What is the role of excipients in trihexylphenidyl hydrochloride formulations?

Excipients improve stability, bioavailability, and patient tolerability of trihexylphenidyl hydrochloride (THP). As an anticholinergic agent used for Parkinson’s disease and drug-induced extrapyramidal symptoms, THP’s formulation requires specific excipients to optimize its therapeutic performance.

Which excipients are typically selected for THP formulations?

Table 1 lists common excipients based on formulation type.

Excipient Type	Function	Examples	Considerations
Disintegrants	Facilitate tablet breakup	Croscarmellose sodium, sodium starch glycolate	Compatibility with THP, rapid disintegration
Binders	Hold ingredients together	Povidone K30, hydroxypropyl cellulose	Stability under manufacturing conditions
Fillers/Diluents	Adjust tablet size	Lactose monohydrate, microcrystalline cellulose	Avoid lactose in lactose intolerance
Lubricants	Ensure manufacturability	Magnesium stearate	Minimal impact on dissolution
Preservatives	Prevent microbial growth	Phenoxyethanol	Stability with other excipients

How does excipient selection influence commercial opportunities?

1. Formulation flexibility: Using excipients that enable alternative delivery forms (liquids, patches, implantable) can expand market reach. For example, lipid-based excipients can support transdermal systems.

2. Cost optimization: Sourcing inexpensive, readily available excipients reduces production costs. Microcrystalline cellulose and lactose are cost-effective options.

3. Regulatory compliance: Excipients with established safety profiles and well-documented stability facilitate faster approval processes, reducing time to market.

4. Patient-centric formulations: Introducing sugar-free or allergen-free excipients broadens patient eligibility, key in markets with strict dietary or allergy considerations.

What are the regulatory considerations for excipients in THP formulations?

• FDA and EMA guidelines specify that excipients must be pharmaceutically acceptable, non-toxic, and support the product’s stability.
• Excipients must have established safety data in relevant dosage forms and populations.
• Changes in excipient source or type require supplemental regulatory filings (e.g., prior approval in ANDA or NDA submissions).

How can formulation innovations unlock market expansion?

• Transdermal patches: Incorporate excipients like permeation enhancers (e.g., oleic acid) to enable needle-free delivery.
• Oral extended-release tablets: Use matrix-forming excipients (e.g., hydroxypropyl methylcellulose) to extend duration of action, improving compliance.
• Injectable formulations: Combine solubilizers and stabilizers (e.g., polysorbate 80) to create injectable liquids, addressing acute management needs.

What are the commercial opportunities stemming from excipient innovations?

• Orphan drug designation: Innovation in delivery forms targeting Parkinson’s disease or extrapyramidal side effects can enhance exclusivity periods.
• Combination therapies: Formulations combining THP with other agents (e.g., L-dopa derivatives) with suitable excipients open new therapeutic markets.
• Over-the-counter (OTC) products: Developing low-dose formulations with excipients suitable for OTC availability may broaden access.

Summary of key points

• Excipients support bioavailability, stability, and patient adherence of THP formulations.
• Selection depends on the administration route, market demands, and regulatory landscape.
• Formulation innovations using excipients can unlock new delivery systems, reducing manufacturing costs and expanding indications.
• Regulatory compliance and safety data for excipients are critical for market approval.
• Excipient strategies directly influence product lifecycle management and commercial success.

Key Takeaways

• Excipient choice in THP formulations impacts product stability, bioavailability, and patient compliance.
• Transdermal and extended-release formulations provide growth avenues.
• Cost-effective, FDA- and EMA-compliant excipients facilitate faster market entry.
• Innovative delivery systems can address unmet needs and broaden market presence.
• Regulatory diligence in excipient selection ensures sustained product success.

FAQs

1. What are the primary excipients used in triple-hydrochloride tablets?
   Disintegrants, binders, fillers, lubricants, and preservatives.

2. How can excipients improve the bioavailability of THP?
   By optimizing tablet disintegration and dissolution, or enabling alternative delivery routes.

3. What excipients facilitate transdermal delivery of THP?
   Permeation enhancers such as oleic acid, surfactants, and suitable polymers.

4. Are there concerns regarding excipient safety in long-term use?
   Yes, excipients must have established safety profiles; long-term safety assessments are essential.

5. Can excipient innovation support biosimilar development of THP?
   While biosimilars are not applicable, excipient innovations can support generic absorption and efficacy.

---

References

[1] European Medicines Agency. (2020). Guideline on excipients in the dossier for application for marketing authorization of a medicinal product. EMA/CHMP/QWP/545525/2018.